Generation of affibody molecules specific for HPV16 E7 recognition

Oncotarget

Volumn 7, Issue 45, 2016, Pages 73995-74005

  Xue, Xiangyang ^a   Wang, Bingbing ^a   Du, Wangqi ^a   Zhang, Chanqiong ^a   Song, Yiling ^a   Cai, Yiqi ^a   Cen, Danwei ^a   Wang, Ledan ^a   Xiong, Yirong ^a   Jiang, Pengfei ^a   Zhu, Shanli ^a   Zhao, Kong Nan ^a   Zhang, Lifang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Affibody molecules; Cervical cancer; E7; Human papillomavirus; In vivo imaging

Indexed keywords

AFFIBODY MOLECULE; PROTEIN E7; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; ANTIBODY; HYBRID PROTEIN; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIOPHAGE; BINDING AFFINITY; BIOSENSOR; CANCER DIAGNOSIS; CASKI CELL LINE; CERVICAL CANCER CELL LINE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IN VIVO STUDY; MOLECULAR IMAGING; MOLECULAR RECOGNITION; MOUSE; MOUSE MODEL; NONHUMAN; PEPTIDE LIBRARY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN LOCALIZATION; SIHA CELL LINE; TUMOR XENOGRAFT; UTERINE CERVIX CANCER; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; DIAGNOSTIC IMAGING; FEMALE; FLUORESCENCE IMAGING; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROCEDURES; PROTEIN DOMAIN; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICE; MOLECULAR IMAGING; OPTICAL IMAGING; PAPILLOMAVIRUS E7 PROTEINS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECOMBINANT FUSION PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 84995745245     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12174     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90. doi: 10.3322/caac.20107.
2. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013; 31:H1-31. doi: 10.1016/j. vaccine.2013.10.003.
3. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology. 1991; 184:9-13.
4. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study G. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348:518-27. doi: 10.1056/NEJMoa021641.
5. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJ, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014; 383:524-32. doi: 10.1016/S0140-6736(13)62218-7.
6. Badaracco G, Venuti A, Sedati A, Marcante ML. HPV16 and HPV18 in genital tumors: Significantly different levels of viral integration and correlation to tumor invasiveness. J Med Virol. 2002; 67:574-82. doi: 10.1002/jmv.10141.
7. Hopman AH, Smedts F, Dignef W, Ummelen M, Sonke G, Mravunac M, Vooijs GP, Speel EJ, Ramaekers FC. Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. J Pathol. 2004; 202:23-33. doi: 10.1002/path.1490.
8. Romanczuk H, Howley PM. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Natl Acad Sci U S A. 1992; 89:3159-63.
9. Kelley ML, Keiger KE, Lee CJ, Huibregtse JM. The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J Virol. 2005; 79:3737-47.
10. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990; 63:1129-36.
11. Wang J, Sampath A, Raychaudhuri P, Bagchi S. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells. Oncogene. 2001; 20:4740-9.
12. Ying H, Xiao ZX. Targeting retinoblastoma protein for degradation by proteasomes. Cell Cycle. 2006; 5:506-8.
13. White EA, Sowa ME, Tan MJ, Jeudy S, Hayes SD, Santha S, Munger K, Harper JW, Howley PM. Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. Proc Natl Acad Sci U S A. 2012; 109:E260-7. doi: 10.1073/pnas.1116776109.
14. Collins AS, Nakahara T, Do A, Lambert PF. Interactions with pocket proteins contribute to the role of human papillomavirus type 16 E7 in the papillomavirus life cycle. J Virol. 2005; 79:14769-80. doi: 10.1128/JVI.79.23.14769-14780.2005.
15. Zhang L, Wu J, Ling MT, Zhao L, Zhao KN. The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses. Mol Cancer. 2015; 14:87. doi: 10.1186/s12943-015-0361-x.
16. Wu J, Chen J, Zhang L, Masci PP, Zhao KN. Four major factors regulate phosphatidylinositol 3-kinase signaling pathway in cancers induced by infection of human papillomaviruses. Curr Med Chem. 2014; 21:3057-69.
17. Wu J, Chen C, Zhao KN. Phosphatidylinositol 3-kinase signaling as a therapeutic target for cervical cancer. Curr Cancer Drug Targets. 2013; 13:143-56.
18. Lofblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010; 584:2670-80. doi: 10.1016/j. febslet.2010.04.014.
19. Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Hoiden-Guthenberg I, Widstrom C, Carlsson J, Tolmachev V, Stahl S, Nilsson FY. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006; 66:4339-48. doi: 10.1158/0008-5472. CAN-05-3521.
20. Friedman M, Nordberg E, Hoiden-Guthenberg I, Brismar H, Adams GP, Nilsson FY, Carlsson J, Stahl S. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng Des Sel. 2007; 20:189-99. doi: 10.1093/protein/gzm011.
21. Tolmachev V, Malmberg J, Hofstrom C, Abrahmsen L, Bergman T, Sjoberg A, Sandstrom M, Graslund T, Orlova A. Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551. J Nucl Med. 2012; 53:90-7. doi: 10.2967/jnumed.111.090829.
22. Gao J, Chen K, Miao Z, Ren G, Chen X, Gambhir SS, Cheng Z. Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials. 2011; 32:2141-8. doi: 10.1016/j.biomaterials.2010.11.053.
23. Gostring L, Malm M, Hoiden-Guthenberg I, Frejd FY, Stahl S, Lofblom J, Gedda L. Cellular effects of HER3-specific affibody molecules. PLoS One. 2012; 7:e40023. doi: 10.1371/journal.pone.0040023.
24. Cheng Z, De Jesus OP, Namavari M, De A, Levi J, Webster JM, Zhang R, Lee B, Syud FA, Gambhir SS. Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med. 2008; 49:804-13. doi: 10.2967/jnumed.107.047381.
25. Li J, Lundberg E, Vernet E, Larsson B, Hoiden-Guthenberg I, Graslund T. Selection of affibody molecules to the ligandbinding site of the insulin-like growth factor-1 receptor. Biotechnol Appl Biochem. 2010; 55:99-109. doi: 10.1042/BA20090226.
26. Wikman M, Rowcliffe E, Friedman M, Henning P, Lindholm L, Olofsson S, Stahl S. Selection and characterization of an HIV-1 gp120-binding affibody ligand. Biotechnol Appl Biochem. 2006; 45:93-105. doi: 10.1042/BA20060016.
27. Tolmachev V, Orlova A, Nilsson FY, Feldwisch J, Wennborg A, Abrahmsen L. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther. 2007; 7:555-68. doi: 10.1517/14712598.7.4.555.
28. Nord K, Nilsson J, Nilsson B, Uhlen M, Nygren PA. A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng. 1995; 8:601-8.
29. Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol. 1997; 15:772-7. doi: 10.1038/nbt0897-772.
30. Phaeton R, Gutierrez J, Jiang Z, Karabakhtsian RG, Albanese J, Sunkara J, Fisher DR, Goldberg GL, Dadachova E. Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer. Immunotherapy. 2015; 7:631-40. doi: 10.2217/imt.15.18.
31. Guo C, Liu K, Zheng Y, Luo H, Chen H, Huang L. Apoptosis induced by an antagonist peptide against HPV16 E7 in vitro and in vivo via restoration of p53. Apoptosis. 2011; 16:606-18. doi: 10.1007/s10495-011-0594-0.
32. Tan S, de Vries EG, van der Zee AG, de Jong S. Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer. Curr Cancer Drug Targets. 2012; 12:170-84.
33. Accardi L, Paolini F, Mandarino A, Percario Z, Di Bonito P, Di Carlo V, Affabris E, Giorgi C, Amici C, Venuti A. In vivo antitumor effect of an intracellular single-chain antibody fragment against the E7 oncoprotein of human papillomavirus 16. Int J Cancer. 2014; 134:2742-7. doi: 10.1002/ijc.28604.
34. Li JG, Li L, Zhang SW, Wei X. HPV16E7-specific siRNA inhibits cell proliferation in CaSki cells. Cell Biochem Biophys. 2015; 71:529-34. doi: 10.1007/s12013-014-0223-y.
35. Jung HS, Rajasekaran N, Song SY, Kim YD, Hong S, Choi HJ, Kim YS, Choi JS, Choi YL, Shin YK. Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo. Int J Mol Sci. 2015; 16:12243-60. doi: 10.3390/ijms160612243.
36. Orlova A, Tolmachev V, Pehrson R, Lindborg M, Tran T, Sandstrom M, Nilsson FY, Wennborg A, Abrahmsen L, Feldwisch J. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 2007; 67:2178-86. doi: 10.1158/0008-5472.CAN-06-2887.
37. Wang B, Tu J, Lv Y, Hou B, Liu Q, Lin X, Chen S, Xue X, Zhu S, Zhang L. Expression of HPV16 E7 protein and preparation of its polyclonal antibody. [Article in Chinese]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014; 30:167-70.